Bolu Yang

Dr. Bolu Yang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YFYichen E Fang
Yichen E Fang
ZZZhixian Zhang
Zhixian Zhang
RWRay Wang
Ray Wang
BYBolu Yang
Bolu Yang
CCChen Chen
Chen Chen
LYLijing Yan
Lijing Yan
Background: Rapid advancements in eHealth and mobile health (mHealth) technologies have driven researchers to design and evaluate numerous technology-based interventions to promote smoking cessation. The evolving nature of cessation interventions emphasizes a strong need for knowledge synthesis. Objective: This systematic review and meta-analysis aimed to summarize recent evidence from randomized controlled trials regarding the effectiveness of eHealth-based smoking cessation interventions in promoting abstinence and assess nonabstinence outcome indicators, such as cigarette consumption and user satisfaction, via narrative synthesis. Methods: We searched for studies published in English between 2017 and June 30, 2022, in 4 databases: PubMed (including MEDLINE), PsycINFO, Embase, and Cochrane Library. Two independent reviewers performed study screening, data extraction, and quality assessment based on the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework. We pooled comparable studies based on the population, follow-up time, intervention, and control characteristics. Two researchers performed an independent meta-analysis on smoking abstinence using the Sidik-Jonkman random-effects model and log risk ratio (RR) as the effect measurement. For studies not included in the meta-analysis, the outcomes were narratively synthesized. Results: A total of 464 studies were identified through an initial database search after removing duplicates. Following screening and full-text assessments, we deemed 39 studies (n=37,341 participants) eligible for this review. Of these, 28 studies were shortlisted for meta-analysis. According to the meta-analysis, SMS or app text messaging can significantly increase both short-term (3 months) abstinence (log RR=0.50, 95% CI 0.25-0.75; I2=0.72%) and long-term (6 months) abstinence (log RR=0.77, 95% CI 0.49-1.04; I2=8.65%), relative to minimal cessation support. The frequency of texting did not significantly influence treatment outcomes. mHealth apps may significantly increase abstinence in the short term (log RR=0.76, 95% CI 0.09-1.42; I2=88.02%) but not in the long term (log RR=0.15, 95% CI −0.18 to 0.48; I2=80.06%), in contrast to less intensive cessation support. In addition, personalized or interactive interventions showed a moderate increase in cessation for both the short term (log RR=0.62, 95% CI 0.30-0.94; I2=66.50%) and long term (log RR=0.28, 95% CI 0.04-0.53; I2=73.42%). In contrast, studies without any personalized or interactive features had no significant impact. Finally, the treatment effect was similar between trials that used biochemically verified or self-reported abstinence. Among studies reporting outcomes besides abstinence (n=20), a total of 11 studies reported significantly improved nonabstinence outcomes in cigarette consumption (3/14, 21%) or user satisfaction (8/19, 42%). Conclusions: Our review of 39 randomized controlled trials found that recent eHealth interventions might promote smoking cessation, with mHealth being the dominant approach. Despite their success, the effectiveness of such interventions may diminish with time. The design of more personalized interventions could potentially benefit future studies. Trial Registration: PROSPERO CRD42022347104; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=347104

16 August 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
YJYufei Jia
Yufei Jia
WJWeixi Jiang
Weixi Jiang
BYBolu Yang
Bolu Yang
STShenglan Tang
Shenglan Tang
QLQian Long
Qian Long
This systematic review examined cancer care costs, the financial burden for patients, and their economic coping strategies in mainland China. We included 38 quantitative studies that reported out-of-pocket payment for cancer care and patients’ coping strategies in English or Chinese (PROSPERO: CRD42021273989). We searched PubMed, Embase, Ovid, Web of Science, Cochrane, CNKI, and Wanfang Data from 1 January 2009 to 10 August 2022. We referred to the standards for reporting observational studies to assess the methodological quality and transparent reporting of the included studies and reported the costs narratively. Annual mean medical costs (including inpatient and outpatient costs and fees for self-purchasing drugs) ranged from USD 7421 to USD 10,297 per patient. One study investigated medical costs for 5 years and indicated that inpatient costs accounted for 51.6% of the total medical costs, followed by self-purchasing drugs (43.9%). Annual medical costs as a percentage of annual household income ranged from 36.0% to 63.1% with a metaproportion of 51.0%. The common coping strategies included borrowing money and reduction of household expenses and expenses from basic health services. Costs of inpatient care and self-purchasing drugs are major drivers of medical costs for cancer care, and many affected households shoulder a very heavy financial burden.

27 March 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
XCXingxing Chen
Xingxing Chen
EGEnying Gong
Enying Gong
JTJie Tan
Jie Tan
ETElizabeth L. Turner
Elizabeth L. Turner
JGJohn A. Gallis
John A. Gallis
LYLijing Yan
Lijing Yan
Background: Despite growing evidence of primary care-based interventions for chronic disease management in resource-limited settings, long-term post-trial effects remain inconclusive. We investigated the association of a 12-month system-integrated technology-enabled model of care (SINEMA) intervention with mortality outcomes among patients experiencing stroke at 6-year post-trial. Methods and findings: This study (clinicltiral.gov registration number: NCT05792618) is a long-term passive observational follow-up of participants and their spouse of the SINEMA trial (clinicaltrial.gov registration number: NCT03185858). The original SINEMA trial was a cluster-randomized controlled trial conducted in 50 villages (clusters) in rural China among patients experiencing stroke during July 2017–July 2018. Village doctors in the intervention arm received training, incentives, and a customized mobile health application supporting monthly follow-ups to participants who also received daily free automated voice-messages. Vital status and causes of death were ascertained using local death registry, standardized village doctor records, and verbal autopsy. The post-trial observational follow-up spanned from 13- to 70-months post-baseline (up to April 30, 2023), during which no intervention was requested or supported. The primary outcome of this study was all-cause mortality, with cardiovascular and stroke cause-specific mortality also reported. Cox proportional hazards models with cluster-robust standard errors were used to compute hazard ratios (HRs) and 95% confidence intervals (95% CIs), adjusting for town, age, and sex in the main analysis model. Analyses were conducted on an intention-to-treat basis. Of 1,299 patients experiencing stroke (mean age 65.7 years, 42.6% females) followed-up to 6 years, 276 (21.2%) died (median time-to-death 43.0 months [quantile 1–quantile 3: 26.7–56.8]). Cumulative incidence of all-cause mortality was 19.0% (121 among 637) in the intervention arm versus 23.4% (155 among 662) in the control arm (HR 0.73; 95% CI 0.59, 0.90; p = 0.004); 14.4% versus 17.7% (HR 0.73; 95% CI 0.58, 0.94; p = 0.013) for cardiovascular cause-specific mortality; and 6.0% versus 7.9% (HR 0.71; 95% CI 0.44, 1.15; p = 0.16) for stroke cause-specific mortality. Although multisource verification was used to verify the outcomes, limitations exist as the survey- and record-matching-based nature of the study, unavailability of accurate clinical diagnostic records for some cases and the potential confounders that may influence the observed association on mortality. Conclusions: Despite no observed statistically difference on stroke cause-specific mortality, the 12-month SINEMA intervention, compared with usual care, significantly associated with reduced all-cause and cardiovascular cause-specific mortality during 6 years of follow-up, suggesting potential sustained long-term benefits to patients experiencing stroke.

11 September 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
BYBolu Yang
Bolu Yang
EGEnying Gong
Enying Gong
XCXingxing Chen
Xingxing Chen
JTJie Tan
Jie Tan
NPNicholas Peoples
Nicholas Peoples
LYLijing Yan
Lijing Yan
Background: To bridge the gap between clinical guidelines and suboptimal stroke management in rural settings, we conducted an implementation trial using evidence-based, mobile health–enabled strategies to empower primary care providers in rural China. The system-integrated and digital technology–enabled model of care (SINEMA) model was shown to significantly reduce blood pressure and mortality among people with stroke in rural China. Objective: This study aimed to evaluate the cost-effectiveness of the SINEMA intervention within both the active trial and the post-trial observational periods and its budget impact for potential nationwide scalability. Methods: In the cluster-randomized implementation trial (the SINEMA trial), 50 villages were randomized to either a 1-year intervention (2017-2018) or usual care, with 1299 patients with stroke followed up until 2022-2023—6 years after the trial baseline. The incremental cost-effectiveness ratios (ICER) for systolic blood pressure reduction and quality-adjusted life year gains were estimated from a health sector perspective. Both probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of the findings. Additionally, a budget impact analysis was performed from a public payer perspective to estimate the per-capita and total costs of national scale-up under 2 scenarios: a standalone intervention and integration into the existing basic public health service system. Results: The ICER per 1 mmHg systolic blood pressure reduction was $8.4 for the within-trial estimation. The ICER per quality-adjusted life year gained was $837.9 within-trial and $727.9 post-trial, both highly cost-effective relative to any commonly adopted thresholds and robust in sensitivity analyses. The first-year budget impact ranged from $115.6 million to $197.7 million in the 2 scenarios, reducing to $46.6 million to $78.7 million by year 5, with a per-capita cost of $0.03-$0.06. Conclusions: Our findings demonstrate that the SINEMA intervention was cost-effective during the trial period and remained so throughout the 6-year sustainability observation period. These results highlight the potential of adopting similar health system–integrated, mobile health–enabled strategies to enhance the management of stroke and other chronic diseases in resource-limited settings. Trial Registration: ClinicalTrials.gov NCT0318585, ClinicalTrials.gov NCT05792618; https://clinicaltrials.gov/study/NCT03185858 and https://clinicaltrials.gov/study/NCT05792618 International Registered Report Identifier (IRRID): RR2-10.3389/fneur.2023.1145562

27 November 2024 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
BYBolu Yang
Bolu Yang
RWRay Wang
Ray Wang
QSQianqian Shen
Qianqian Shen
JWJia Wang
Jia Wang
QLQian Long
Qian Long
Introduction: Since the ratification of the Framework Convention on Tobacco Control in 2005, mainland China has experienced notable delays in implementing the Framework Convention on Tobacco Control. This study aims to examine the legislation and implementation of smoke-free laws in different cities in mainland China, with a particular focus on identifying factors that contribute to these differences. Aims and Methods: Through a literature review and policy mapping, we gathered information on the variations in smoke-free laws’ legislation and implementation across mainland China. To delve deeper into the local specifics of implementation and the factors contributing to these variations, qualitative interviews were conducted with 16 key stakeholders in two selected cities. This group included former policy makers, policy experts, enforcement officers, and public venue owners. Results: Although the revision of Healthy Cities standards advocates for the enactment of smoking bans post-2021, less than half of these cities have implemented comprehensive smoke-free laws. This phenomenon can be partly attributed to the tobacco industry’s significant influence in the legislative process and to policy makers’ limited understanding of smoking rooms/areas being temporary measures without setting clear end dates for transition periods. We also identified inconsistent implementation across selected cities, attributed to inadequate coordination and workforce shortages. Conclusions: Our study reveals significant variations and delays in the adoption of smoke-free laws across different cities in mainland China. We identify key factors contributing to this disparity, underscoring the urgent need for targeted measures to address these challenges, such as setting up a coordinated department and promoting policy advocacy. Implications: This study reveals geographical disparities in the legislative progress and enforcement effectiveness of smoke-free laws in mainland China. Persistent interference from the tobacco industry has obstructed the establishment of comprehensive smoke-free laws. Additionally, policy makers’ limited awareness of the harm caused by designated smoking areas, regional economic disparities, and inadequate interdepartmental coordination have impeded effective policy implementation. These findings underscore the urgent need to set enforcement goals aligned with local economic contexts and strengthen policy dialogue to empower policy makers and stakeholders to mitigate tobacco industry influence and achieve successful implementation.

17 February 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CMChenxi'nan Ma
Chenxi'nan Ma
LWLei Wu
Lei Wu
YLYaxi Li
Yaxi Li
BYBolu Yang
Bolu Yang
JTJie Tan
Jie Tan
TJTazeen H. Jafar
Tazeen H. Jafar
Key Points: Multicomponent interventions with two or more intervention strategies are increasingly used to manage patients with CKD G3-G4. Existing multicomponent interventions had a modest effect on slowing CKD progression, although the certainty of evidence was low for eGFR and moderate for eGFR slope. Among multicomponent interventions, physician-led team-based care seemed superior to non–physician-led team-based care, albeit the clinical relevance of the benefit was modest. Background: Various multicomponent interventions (MCIs) have been increasingly used for managing patients with CKD G3-G4, but they have not been systematically evaluated for the collective evidence of their effectiveness. Hence, we conducted this systematic review and meta-analysis to evaluate the effectiveness of MCIs in delaying CKD progression and improving health outcomes in patients with CKD G3-G4. Methods: We completed a systematic literature search in PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Cumulative Index to Nursing and Allied Health Literature from inception to July 30, 2025. We included randomized controlled trials studying the effectiveness of MCIs lasting at least 6 months among patients with CKD G3-G4. We used random-effects meta-analyses to estimate the effectiveness of MCIs on the primary outcome, eGFR, and secondary outcomes, including other kidney function indicators, CKD risk factors, and adverse events. Results: Nineteen randomized controlled trials (36,296 patients with CKD G3-G4; median follow-up of 24 months) were included. Components of MCI included a mix of behavioral modifications, guideline-directed medical therapy, enabling technology components, and team-based care. Compared with control, MCIs were associated with small improvements in eGFR (mean difference [MD]=1.18 ml/min per 1.73 m 2 ; 95% confidence interval [CI], 0.09 to 2.27; 19 trials, low certainty of evidence), eGFR slope (MD=0.61 ml/min per 1.73 m 2 /yr; 95% CI, 0.16 to 1.06; six trials, moderate certainty of evidence), and a moderate reduction in HbA1c (MD=−0.26; 95% CI, −0.49 to−0.02; nine trials, low certainty of evidence). No statistically significant effects were observed for albuminuria, BP, or adverse events. Conclusions: Our findings suggest the potential role of MCIs in delaying CKD progression and improving glycemic control among patients with CKD G3-G4. Nonetheless, the certainty of evidence is low for eGFR and HbA1c and moderate for eGFR slope, suggesting overall modest clinical relevance. High-quality studies are needed to confirm the effectiveness, cost-effectiveness, and scalability of MCIs for this high-risk patient group.